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Objective(s): Injectable insulin is the most widely used therapy in patients with type 1 diabetes which 
has several disadvantages. The present study was aimed to evaluate the efficacy of injectable insulin on 
diabetes mellitus-related complications in comparison to orally encapsulated insulin nanoparticles.
Materials and Methods: This study involved 42 Wistar rats separated into 5 groups, including control 
(C), diabetic control (D), diabetic receiving regular insulin (INS), diabetic receiving encapsulated 
insulin nanoparticle (INP), and diabetic receiving chitosan for two months. Biochemical parameters in 
serum and urine were measured using spectrophotometric or ELISA methods. mRNA levels of kidney 
injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were evaluated 
using quantitative PCR. 
Results: There were no significant differences between the two forms of insulin in controlling the 
glycemic condition (P-value>0.05), but oral INP was more effective in correcting diabetic dyslipidemia 
in comparison to injectable insulin (P-value<0.05). Urine volume and creatinine excretion were 
significantly modulated by insulin and oral INP in diabetic groups (P-value<0.05), although the effects 
of INP on the modulation of execration of urea, acid uric, and albumin was more dramatic. Oral INP 
caused a significant decrease in urine concentration of KIM-1 and NGAL as well as expression of KIM-1 
in renal tissue (P-value<0.05).
Conclusion: Our results suggested that oral INP is more effective than injectable insulin in modulation 
of urine and serum diabetic-related parameters.
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Introduction
Diabetes mellitus (DM) is a metabolic disorder 
defined by hyperglycemia and impaired metabolism 
of macromolecules (1). According to a report by the 
international diabetes federation (IDF), more than 400 
million people (20–79 years old) suffered from DM  in 
2017 and this number is expected to go beyond 600 
million by 2045 (2). Ethologically, DM is categorized 
as type 1 diabetes (T1D), largely resulting from 
autoimmune destruction of insulin-producing β-cells 
and defect in insulin production, and type 2 Diabetes 
(T2D) which may be due to insulin resistance in 
peripheral tissues such as muscle and adipose. Generally, 
chronic clinical complications of DM are divided into 
macrovascular complications such as cardiovascular 
disease (CVD), and microvascular complications
including nephropathy, retinopathy, and neuropathy (3). 
There are several mechanisms involved in hyperglycemia-
induced DM complications which include induction of 
polyol pathway, diacylglycerol (DAG)/protein kinase 
C (PKC) signaling pathway, free radicals production, 
stimulation of advanced glycation end products (AGE) 
formation, and activation of hexosamine pathway (3). 
Previous results showed that hyperglycemia disrupts 
vascular homeostasis mainly through inhibitory effects 
on several factors including vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), 
activated protein C (APC), and insulin (4).
One of the major complications of DM that may lead 
to end stage renal disease (ESRD) is diabetic kidney 
disease (DKD) (5, 6). Previous evidence revealed that 
approximately 30% of patients with T1D and 40% of 
patients with T2D suffered from this complication (7). 
In general, hyperglycemia induces renal damage by 
different mechanisms such as change in glomerulus 
hemodynamic, defect in endothelial cell function, 
changes in the basal membrane structure, and podocyte 
injury (8). There are several markers for evaluation of 
DKD; Kidney injury molecule 1 (KIM-1) and Neutrophil 
gelatinase-associated lipocalin (NGAL) are among 
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the new markers, which based on the Food and Drug 
Administration (FDA) reports might be appropriate for 
kidney injury evaluation (9, 10).    
Insulin therapy is the most common method for 
glycemic control in T1D patients and some of the T2D 
patients (11). Subcutaneous injection is one of the routine 
methods for insulin delivery. However, this method has 
some disadvantages such as pain at the injection site, 
lipoatrophy, trauma, skin hypertrophy, increased risk 
of infection, as well as aversion to injection in public 
places (12, 13). It is thought that oral administration of 
insulin not only overcomes these limitations, but also 
it may mimic the physiological conditions in a better 
way in comparison to subcutaneous injection (14). This 
strategy, nevertheless, has two challenging issues: first, 
destructive effects of gastrointestinal tract on the orally 
administrated insulin, and second, the low permeability 
of insulin across the cell membrane due to its size and 
its hydrophobicity properties (15).
One of the promising strategies in this context 
is to encapsulate insulin into carriers in order to 
improve its delivery efficacy and its bioavailability 
(16-18). Nanoparticles are appropriate candidates 
among carriers that are applied by several 
pharmaceutical companies. Chitosan is a linear cationic 
heteropolysaccharide composed of D-glucosamine and 
N-acetyl-D-glucosamine derived from deacetylation of 
chitin (19). Chitosan is among the most widely used 
carriers in drug delivery due to its interesting properties 
such as high biocompatibility, high biodegradability, 
non-toxicity effects as well as high stability (20, 21). 
Furthermore, cationic chitosan is capable of interacting 
with anionic glycoproteins on intestinal epithelial cells 
membrane, thereby passing more easily through  cell 
tight junctions (22).
Given the importance of DKD evaluation as one of the 
main complication of DM, and improving the efficiency 
of insulin delivery, we studied the effects of orally 
administrated encapsulated insulin nanoparticles on 
different parameters in serum and urine of T1D rats in 
comparison to injectable insulin.
Materials and Methods
Insulin nanoparticle synthesis
Synthesis of quaternized N-aryl derivatives of chitosan
Briefly, 3 g of chitosan powder (Primex) was added 
to 300 ml of acetic acid 1% and mixed properly to make 
a jelly solution. After adjustment of pH to 5.5 by NaOH 
1N, 2.5 g of 4-N,N-dimethyl Benz aldehyde (Merck) 
was added to the solution and then mixed to produce a 
phosphorus green suspension. The procedure continued 
by adding NaOH to the suspension, separation of 
sediment and then washing by methanol. Afterward, 2 
g of dried sediment was mixed with 70 ml of N-methyl 
pyrrolidone (Merck) and heated at 100 °C for 48 hr. 
After this step, 1 gr potassium iodide was added and 
then heated at 50 °C following by adding 2 ml of NaOH 
1N and 12 ml of methyl Iodide. Finally, after heating the 
mixture for 24 hr at 50 °C, 2 liters of acetone were added, 
the sediment then was separated using a Buchner funnel 
and dried. Furthermore, characterization of quaternized 
derivatives was evaluated by H-NMR. 
Loading insulin into nanoparticles
Insulin was loaded into nanoparticles by modified 
polyelectrolyte complexation (PEC) method (23). In 
this method, 0.03 g of quaternized and aromatized 
chitosan polymer produced in the previous step was 
added to 30 ml of acetic acid 1% to produce a chitosan 
polymer solution. Insulin with negative charge was 
generated by mixing 0.03 g of lyophilized insulin (Exir 
Pharmaceutical, Iran) in 30 ml acetic acid followed by 
adjustment of pH to 8.2. The insulin solution was added 
(flow of 1 ml/min) to chitosan solution, mixed and 
then centrifuged at 17000 rpm for 20 min to produce 
insulin nanoparticles (INPs) in the sediment phase. The 
supernatant phase was used for evaluation of loading 
and entrapment efficiency. 
Evaluation of physical properties of INPs
Different properties of INPs including size, 
polydispersity, and zeta potential were evaluated by 
Zetasizer ZEN3600 (Malvern instrument, UK) at 25 °C. 
Morphology of INPs was assessed using Transmission 
Electron Microscope (TEM). 
Measurement of loading and entrapment efficiency
The loading efficiency (LE) and entrapment 
efficiency (EE) were studied by high performance liquid 
chromatography (HPLC) (LC 20AD XR, Shimadzu) 
equipped with a vacuum degasser, C18 (250 mm×4.6 
mm, 5 μm) column, and UV-VIS photodiode array 
detector. Twenty-five microliters of the samples was 
injected to HPLC and the mixture of acetonitrile and 
sodium sulfate (1.5:1 v/v respectively) was used as 
mobile phase at 1 ml/min flow rate for 5 min at 25 °C. 
Loading efficiency and entrapment efficiency were 
measured based on the following equation (23):   
      LE%= Total amount of insulin-Free amount of insulin ×100
                                     Weight of nanoparticles
EE%= Total concentraion of insulin-Free concentration of insulin×100
Total concentraion of insulin
Lyophilization and encapsulation of INPs
INPs were dissolved in mannitol 5% and then 
placed in a freeze dryer Lyotrap Plus (LTE Scientific 
Ltd, Oldham, UK) at -46 °C and 0.07 mbar pressure for 
48 hr. Finally, lyophilized INPs were encapsulated by 
preclinical capsules (Capsugel, Belgium).
 
Coating of INPs
Prepared INPs were coated by Eudragit L100 (Merck, 
Germany). In this method, 20 g of Eudragit L100 powder 
was added to NaOH 1N and stirred for 5 days to produce 
a jelly solution. Afterward, preclinical capsules filled by 
lyophilized INPs were added to this solution and then 
dried. Coating of the encapsulated insulin nanoparticle 
with Eudragit L100 led to release of INPs only in the 
jejunum and protected it against the destructive effects 
of the stomach. 
Evaluation of insulin release 
Simulated gastric fluid (SGF) and simulated intestinal 
fluid (SIF) were used for in vitro release assessment of 
nanoparticles in the stomach and intestine, respectively. 
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SGF was prepared by adding hydrochloric acid solution 
(0.2 N, 39 ml) to sodium chloride solution (0.2 N, 250 
ml), and the volume was then adjusted to 1000 ml with 
deionized water and pH was maintained at 2.2. SIF 
was provided by dissolving KH2PO4 (6.8 g) in 250 ml of 
deionized water. The solution was mixed with NaOH (0.2 
N, 77 ml) and then adjusted to 1000 ml using deionized 
water, while the pH was maintained at 6.8. Encapsulated 
INPs coated by Eudragit L100 were added into SGF 
medium and after 15, 30, 45, 60, 75, 90, and 120 min, 
1 ml solution was sampled from SGF and analyzed by 
HPLC. Finally, encapsulated INPs were transferred 
from SGF to SIF and sampling was repeated and insulin 
release was measured by HPLC.       
Animals and study design
Forty-two adult male Wistar rats (214–244 g) were 
involved in this study. They were kept under standard 
conditions (12-hr dark/light cycle at 22±2 °C). The 
animals were randomly divided into 5 groups: Group 
C: normal control treated with normal saline (n=8), 
group D: diabetic control (n=10), D+INS: diabetic group 
treated with regular insulin (5 u/kg daily, subcutaneous 
injection) (Exir Pharmaceutical Company, Iran)  (n=8) 
(24), D+INP: diabetic group treated with capsulated 
INPs (30 u/kg daily, orally) (n=8), and D+ Chitosan: 
diabetic group treated with chitosan (15 mg/kg, by 
gavage) (n=8). The treatment course was 60 days. The 
induction of T1D was done by streptozotocin (STZ, 
Sigma) (60 mg/kg; subcutaneous injection) dissolved 
in citrate buffer (0.1 M, pH: 4.5). Induction of T1D was 
confirmed after 72 hr by measurement of FBS using a 
glucometer (Accuchek; Roche, Germany). Rats whose 
FBS levels were beyond 250 mg/dl were regarded as 
diabetic. At the end of treatment, the animals were 
transferred to metabolic cages to collect 24-hr urine 
then anesthetized by ketamine (50 mg/kg). After 
collecting blood samples (from vena cava) rats then 
were sacrificed. Kidney tissues were separated, and 
liquid nitrogen was used to freeze and save them at -70 
°C. The Medical Ethics Committee of Abadan Faculty of 
Medical Sciences approved all procedures of the current 
study (IR. ABADANUMS.REC. 1395.84)
Lipid profile
Measurement of the rats’ lipid profile including 
triglycerides (TG), total cholesterol TC, and high density 
lipoprotein cholesterol (HDL-C) was done by a kit (Pars 
Azmun, Iran) while low density lipoprotein cholesterol 
(LDL-C) was calculated using the Friedewald formula.
Measurement of biochemical parameters
The concentrations of urea, uric acid, creatinine, and 
albumin (Alb) were assayed using a kit (Pars Azmun, Iran).
Measurement of NGAL and KIM-1 in urine and plasma
The NGAL and KIM-1 concentrations in plasma and urine 
were assayed using an ELISA kit (Cusabio Biotech, Wuhan, 
China), according to the manufacturer’s instructions.
Measurement of KIM-1 and NGAL expression
Total RNA extraction of renal tissues was done by 
RNX- Plus reagent (Cinnagen, Tehran, Iran). Afterward, 
the Prime Script RT reagent kit (TaKaRa Biotechnology, 
Japan) was used to synthesize complementary DNA 
(cDNA) according to the manufacturer’s instructions. In 
order to perform quantitative Real-Time PCR reaction, 
SYBR premix Ex TaqTM II (TaKaRa Biotechnology, 
Japan) was employed using a Roche Light Cycler 
96 System (Roche Life Science Deutschland GmbH, 
Sandhofer, Germany). Amplification conditions included 
initial denaturation in 95 °С for 30 sec followed by 30 
cycles (95 °С for 20 sec, 58 °С for 30 sec, and 72 °С for 30 
sec). β-actin gene was used to normalize relative gene 
expression. The forward and reverse primers included: 
NGAL, forward: 5’-GATGAACTGAAGGAGCGATTC-3’, 
reverse: 5’-TCGGTGG GAACAGAGAAAAC-3’, KIM-1, 
forward: 5’-ACTCCTGCAGACTGGAATGG-3’, reverse: 
5’-ACTCCTGCAGACTGGAATGG-3’, β-actin, forward: 
5’-TCA TTG ACC TCA ACT ACA-3’, and reverse: 5’- 
CAAAGTTGTCATGGA TGACC- 3’. The relative gene 
expression was calculated by the 2-ΔΔCt method.
Statistical analysis
Data were analyzed using SPSS software version 16.0 
(SPSS Inc., Chicago, USA) and the graph was prepared 
using Graph Pad Prism version 6.0 (Graph Pad Software, 
San Diego, USA). All data were shown as mean±SD. To 
compare the mean of variables, one-way analysis of 
variance (ANOVA) was used followed by Tukey’s test. 
Significance level was set at P<0.05.
Results
H-NMR spectrum of quaternized aromatized chitosan
The H-NMR spectrum of quaternized aromatized 
chitosan is shown in Figure 1. Peaks at 2.3 and 2.7 
ppm are related to the protons of the methyl groups 
of [-N(CH3)2] and [-N+(CH3)3] in methylated aliphatic 
amine. Furthermore, peaks at 3.4 and 3.6 ppm represent 
the protons of the methyl groups of [-N(CH3)2] and 
[-N+(CH3)3] in aromatic amine attached to benzyl ring.   
Characteristics of INPs
The size, zeta potential, and polydispersity of INPs 
before and after lyophilization are presented in Table 
1. Results showed that after lyophilization, these 
parameters increased in comparison to before the 
lyophilization.
Figure1. H-NMR spectra of quaternized aromatized chitosan 
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The LE and EE of INPs were 17.96%±0.45 and 
62.03±0.22, respectively. Evaluation of shape by TEM in 
different magnifications confirmed the spherical shape 
of INPs (Figure 2).  
Release of insulin in SGF and SIF
Figure 3 shows the results of in vitro release 
assessment. The amount of insulin released during 120 
min in SGF was 8.3%. However, this amount was 84.81% 
during 120–360 min in the SIF medium. Therefore it can 
be concluded that coating with Eudragit L100 has been 
effective in releasing insulin into the jejunum.      
General and biochemical parameters
The results of general and biochemical measurements 
are presented in Table 2. Compared with the control 
group, the final body weight significantly decreased 
in the diabetic group (P-value<0.05). Treatment with 
insulin and encapsulated INPs significantly improved 
final body weight (P-value<0.05). Induction of diabetes 
by STZ caused significant increase in FBS (P-value<0.05), 
and insulin treatment in the diabetic group as well as 
encapsulated INPs significantly ameliorated the blood 
Parameters Before lyophilization After lyophilization 
Size (nm) 138.2±31 324.33±22.94 
Zeta potential +9.31±1.18 +13.01± 1.1 
Polydispersity 0.243±0.07 0.345±0.05 
 
  
Table 1. Physical characteristics of insulin nanoparticle (INPs) before and after lyophilization
 
  Figure2. Evaluation of encapsulated insulin nanoparticles by 
transmission electron microscope (TEM)       





































  Figure 3. Release of insulin from encapsulated insulin nanoparticles 
coated by Eudragit L100. Release of insulin in SGF (0-120 min) was 
8.35% and this amount was 84.81% in SIF (120-360 min)
Variable/group C D D+INP D+INS D+ Chitosan 
Initial body weight (gr) 228.04±9.3 230.3±10.4 227.2±9.2 224.2±3.2 226.6±4.9 
Final body weight (gr) 294.8±13.9 194.46.9 a 232.3±6.7 a, b, c 220.1±8.3 a, b, c 199.02±7.1a 
Pre-diabetic FBS (mg/dl) 87.1±7.9 85.3±8.3 85.9±8.1 81.3±9.4 77.5±3.3 
Post-diabetic FBS (mg/dl) 84.5±5.3 321.04±21.2a 338.5±10.1a 328.04±18.7a 322.3±17.4a 
Pre-treatment FBS (mg/dl) 82.06±8.4 407.5±14.6 a 395.8±31.9 a 387.1±19.2 a 397.5±17.1 a 
Final FBS (mg/dl) 81.4±4.1 429.5±15.6 a 221.2±15.5 a, b, c 244±12.6 a, b, c 410.1±16.8 a 
Total cholesterol (mg/dl) 94.5±4.4 150.4±10.6 a 129.2±11.2 a, b 135.8±12.1 a 145.1±11.6 a 
TG (mg/dl) 80.6±9.1 152.1±11.9 a 132.9±15.04 a 140.9±9.7 a 147.06±7.6 a 
LDL-C (mg/dl) 38.3±5.8 110.7±9.5 a 56.1±10.2 b, d 78.3±13.01 a, b 106.2±13.09 a 
HDL-C (mg/dl) 51.4±9.06 31.06±8.06 a 39.6±6.01 34.72±7.1a 30.3±3.7 a 
Creatinine (mg/dl) 0.39±0.16 2.1±0.74 a 1.2±0.24 1.59±0.52 a 2.13±0.73 a 
Urea (mg/dl) 21.1±5.4 48.6±7.8 a 30.9±3.8 b, c 37.04±7.8 a 47.6±6.2 a 
Uric acid (mg/dl) 2.92±0.88 6.7±1.07 a 3.75±0.79 b, c 4.37±0.98 b 6.01±1.36 a 
 
  
Table 2. The effect of insulin and INP on the body weight and biochemical parameters in the serum of the studied groups
Data are presented as mean±SD. FBS; fasting blood sugar, TG; Triglyceride, LDL-C; low-density cholesterol, HDL-C; high-density cholesterol. C, 
healthy control; D, diabetic control; INP, encapsulated insulin nanoparticles (30 U/kg); chitosan (15 U/kg); INS, insulin (5 U/kg daily). a Significantly 
different compared with the control groups. b Significantly different compared with diabetic control groups.c Significantly different compared with 
D+Chitosan groups. d Significantly different compared with D+INS.  P-value<0.01
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glucose (P-value<0.05). However, FBS in diabetic 
groups that received insulin and encapsulated INPs was 
still significantly higher than that for the control group 
(P-value<0.05).
Furthermore, STZ-induced T1D significantly 
increased TG and LDL-C concentrations compared with 
the control group (P-value<0.05), but insulin treatment 
and encapsulated INP remarkably modulated the 
levels of LDL-C (P-value<0.05). STZ-induced diabetes 
significantly increased TG levels compared with the 
controls (P-value<0.05), and treatment with insulin 
and encapsulated INPs did not have a significant effect 
on this level (P-value>0.05). Compared with the control 
group, the concentration of HDL-C in diabetic group and 
diabetic groups that received insulin was significantly 
lower (P-value<0.05), but no significant difference 
was observed between diabetic groups that were 
treated with encapsulated INP and the control group 
(P-value>0.05). 
Compared with the control group, the concentrations 
of urea and creatinine in the diabetic group and diabetic 
that received insulin group experienced a significant 
increase (P-value<0.05). However, encapsulated 
INPs significantly improved urea concentration 
(P-value<0.05). T1D caused a significant increase in 
uric acid (P-value<0.05), and treatment by insulin 
and encapsulated INPs modulated it significantly 
(P-value<0.05). Finally, chitosan was found to have 
no significant effects on body weight and biochemical 
parameters (P-value>0.05).
Measurement of urine parameters
Table 3 indicates the results of urine parameters 
assay. Compared with the control group, urine volume 
in treated and untreated diabetic groups had a 
significant increase (P-value<0.05). However, treatment 
of diabetic groups with insulin and encapsulated INPs 
significantly decreased urine volume (P-value<0.05). 
T1D significantly increased concentration of urine 
urea, uric acid, and creatinine (P-value<0.05), and 
treatment by insulin and encapsulated INPs significantly 
decreased these parameters (P-value<0.05). The effect 
of encapsulated INPs on the reduction of uric acid levels 
was significant in comparison to insulin (P-value<0.05). 
Although T1D significantly increased excretion of 
albumin (P-value<0.05), treatment with encapsulated 
INPs improved it (P-value<0.05). There were no 
significant differences between diabetic groups and 
diabetic groups treated with chitosan (P-value>0.05). 
Treatment with chitosan has no significant effects on 
the urine parameters (P-value>0.05).
Gene expression of KIM-1 and NGAL
Figure 4 presents the results of gene expression of 
KIM-1 and NGAL in renal tissue (A and B, respectively). 
There was a significant increase in the expression of KIM-
Variable/group C D D+INP D+INS D+ Chitosan 
Urine volume (ml/day) 12.8±3.9 52.8±6.3 a 33.6±7.02 a, b, c 37.2±6.1a, b, c 49.6±7.5 a 
Creatinine (mg/day) 8.3±2.71 24.5±5.87a 13.08±1.79 b 15.6±3.36 b 20.52±5.08 a 
Urea (g/day) 0.19±0.04 1.85±0.41a 0.51±0.07 b, c 0.87±0.1a, b, c 1.71±0.19 a 
Uric acid (mg/day) 0.36±0.07 4.1±0.65 a 1.8±0.49 a, b, c, d 2.87±0.25 a, b 3.5±0.46 a 
Albumin (mg/day) 3.9±1.27 13.5±3.4 a 7.5±3.4 b 9.5±2.2a 10.6±3.2a 
 
Table 3. The effect of insulin and INP on the urinary parameters of the studied groups
Data are presented as mean±SD. C, healthy control; D, diabetic control; INP, encapsulated insulin nanoparticles (30 U/kg); chitosan (15 U/kg); INS, 
insulin (5 U/kg daily). a Significantly different compared with control groups. b Significantly different compared with diabetic control groups.c 
Significantly different compared with D+Chitosan groups. d Significantly different compared with D+INS.  P-value<0.05
Figure 4. The effect of injectable insulin and encapsulated insulin nanoparticles on the gene expression of kidney injury molecule 1 (KIM-1) (a) 
and neutrophil gelatinase-associated lipocalin (NGAL) (b) in studied groups. The data are presented as mean±SD. C, healthy control; D, diabetic 
control; INP, encapsulated insulin nanoparticles (30 U/kg); INS, insulin (5 U/kg daily); chitosan (15 U/kg). * Significantly different compared with 
C groups.  ** Significantly different compared with D groups, (P-value<0.05)
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1 in the diabetic group and diabetic group that received 
chitosan compared with the controls (P-value<0.05). 
Encapsulated INPs in diabetic groups significantly 
decreased KIM-1 expression (P-value<0.05). The NGAL 
gene expression also was significantly higher in diabetic 
groups and treated groups with chitosan compared with 
controls, however, treatment with encapsulated INPs 
and insulin in diabetic groups significantly decreased it 
(P-value<0.05).
Concentration of KIM-1 and NGAL in urine and plasma
 The results of KIM-1 and NGAL measurement in 
urine and plasma are presented in Figure 5. STZ-
induced T1D caused significant increase in urinary 
KIM-1 concentration (P-value<0.05), treatment 
with encapsulated INPs as well as insulin, however, 
remarkably decreased its level (P-value<0.05) (Figure 
5A). There was no significant difference between groups 
for plasma concentration of KIM-1(P-value>0.05) 
(Figure 5B). Compared with the controls, the urine 
levels of NGAL in diabetic groups and diabetic groups 
that received chitosan and insulin were significantly 
higher (P-value<0.05). However, encapsulated INPs 
significantly decreased it (P-value<0.05) (Figure 5C). 
No significant difference was found across the studied 
groups in terms of plasma concentration of NGAL 
(P-value>0.05) (Figure 5D). 
Discussion
DM is one of the main challenges in the current 
century and a costly burden on society. Injectable 
insulin is the best choice for treatment of T1D patients 
and some T2D patients. However, in addition to 
several side effects, this method of therapy has many 
psychological consequences for DM patients. Nowadays, 
nanotechnology plays an important role in the 
development of pharmaceutical strategies. The current 
study showed that encapsulated INPs, as well as insulin, 
had considerable effects on the maintenance of the 
body weight and glucose homeostasis. However, INPs 
were more effective in the correction of T1D-induced 
dyslipidemia and renal function. Furthermore, INPs 
had a considerable effect on the modulation of KIM-1, 
NGAL, and renal damage biomarkers, in comparison to 
injectable insulin.
According to the results of our study, STZ-induced 
diabetes decreased body weight. However, insulin and 
INPs counteract with this effect. The loss of weight 
under diabetic conditions has been revealed by previous 
studies (25, 26). Indeed, inability of cells to metabolize 
carbohydrates as a source of energy can induce lipolysis 
and proteolysis, which subsequently lead to weight loss 
in DM conditions (27). As shown in previous studies 
that are in agreement with our results, INPs, as well as 
insulin, could improve body weight in T1D rats (28, 29). 
Insulin promotes glucose uptake, synthesis of glycogen 
and proteins, and generally induces the anabolism 
pathways, therefore, the maintenance of body weight 
in diabetic rats that were treated by injectable insulin 
is not an unexpected issue. However, considerable 
effects of oral INPs in balancing body weight is a point 
worth mentioning. The physiochemical barriers of 
gastrointestinal tracts such as environmental pH, 
hydrolytic enzymes, and cell to cell junctions are the 
main factors that counteract with the passage of orally 
administrated insulin (24). However, in the current 
 
Figure 5. The effect of injectable insulin and encapsulated insulin nanoparticles on the (a) urine kidney injury molecule 1 (KIM-1), (b) plasma KIM-
1, (c) urine neutrophil gelatinase-associated lipocalin (NGAL) and (d) plasma NGAL. Data are presented as mean±SD. C, healthy control; D, diabetic 
control; INP, encapsulated insulin nanoparticles (30 U/kg); INS, insulin (5 U/kg daily); chitosan (15 U/kg). * Significantly different compared with 
C groups.  ** Significantly different compared with D groups. *** Significantly different compared with D+INP groups, (P-value<0.05)
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study, improvement of body weight of T1D rats that 
were treated with orally administrated INP highlights 
the success of our strategies for delivery of insulin.  
STZ caused a considerable increase in FBS, and 
treatment with insulin and INPs significantly decreased 
this level. STZ enters the pancreatic β-cells by glucose 
transporter 29 (GLuT29) and induces DNA alkylation 
that is followed by necrosis and degradation of β-cells. 
Our results showed that encapsulated INPs, as well as 
insulin, could decrease FBS in T1D rats. In agreement 
with our study, Heidarisasan et al. showed that oral 
INPs had considerable effects in reduction of FBS in T1D 
rats model (28). Jamshidi et al. also revealed that oral 
INPs can ameliorate T1D-induced hyperglycemia (29). 
The potential of oral INPs to decrease FBS in T1D rats 
confirms again the efficacy of chitosan nanoparticles in 
delivery of insulin. Chitosan is a polymer that enables 
forming an ionic interaction with the negatively charged 
biomolecules at the epithelial cells of the intestine (30). 
In addition, we used quaternary ammonium in the 
structure of chitosan nanoparticles, positively charged 
nanoparticles with high solubility in a wide range of 
pH therapy were formed (31), resulting in delivery of 
insulin with high efficacy.  
Our results revealed that STZ-induced T1D 
increased the concentrations of  TC, TG, and LDL but 
decreased HDL-C concentrations. In other words, orally 
encapsulated INP was more effective in correcting 
dyslipidemia in comparison to injectable insulin. The 
association between T1D induced by STZ and lipid 
profile has been documented by previous studies. A 
study showed that T1D significantly increased TC and 
TG levels. The proposed mechanism is based on two 
points: first, the concentrations of chylomicron and 
LDL-C are increased due to insulin deficiency in T1D, 
and second, decreasing the activity of lipoprotein 
lipase in T1D condition which eventually leads to 
hypertriglyceridemia (32, 33). Therefore, treatment 
by exogenous insulin could correct lipid profiles in 
T1D patients. The metabolism of orally encapsulated 
INPs is different from injectable insulin in that it is 
transferred directly from the intestine to the liver, and 
based on the central role of the liver in metabolism of 
macromolecules, it is expected that insulin loaded into 
nanoparticles is more effective than injectable insulin 
(34). 
One of the important points about oral administration 
of insulin is the use of a formulation that prevents 
the release of insulin in the stomach. In this study, 
encapsulated INPs were coated by eudragit l100 
polymer which dissolved in the jejunum (pH: 6-7) and 
thereby release of insulin in the small intestine was 
guaranteed. Evaluation of insulin release in the current 
study also confirmed this issue and showed that insulin 
is released considerably in SIF. Another important 
issue regarding the application of nanoparticles in drug 
delivery is the stability of nanoparticles. In this study, 
we used the lyophilization process to improve the 
stability of nanoparticles. On the other hand, the use 
of mannitol during the lyophilization process inhibits 
the accumulation of nanoparticles and degradation of 
insulin.
Furthermore, our findings showed that T1D caused 
increase in urea, uric acid, and creatinine, whereas 
treatment by insulin and INPs significantly decreased 
these parameters. In accordance with our results, 
results by other researchers revealed that treatment 
by encapsulated form of insulin as well as insulin 
decreased the serum concentration of urea (35). 
Increasing the levels of creatinine and urea in DM is 
related to inability of cells to use glucose in DM that is 
compensated by catabolism of proteins, amino acids, 
and phosphocreatine which results in production of 
high levels of urea and creatinine (36, 37). Insulin and 
INP decreased the urea and creatinine concentrations 
by inducing the uptake and metabolism of glucose and 
also decrease in the breakdown of proteins. Uric acid is 
the final product of purine nucleotide metabolism which 
acts as an antioxidant. High levels of uric acid in DM 
might result from elevated production or from excretion 
inability (38). Imbalance between production and 
degradation of free radicals which results in oxidative 
stress is one of the main factors that is involved in DM 
pathogenesis (39). Accordingly, one of the mechanisms 
that improved DM-induced oxidative damage is 
elevation of antioxidant levels. Taken together, it can 
be concluded that high levels of uric acid in T1D rats 
is a defense mechanism to overcome oxidative stress 
(40). Diabetic hyperglycemia disturbs the nicotinamide 
adenine dinucleotide NADH/NAD ratio and is one 
of the main factors involved in oxidative stress (41). 
Accordingly, administration of insulin might ameliorate 
the DM hyperglycemia and improve oxidative stress.
The urinary levels of creatinine, urea, uric acid, and Alb 
were completely increased in T1D rats and significantly 
decreased by insulin and INP administration. The effect 
of orally encapsulated INPs on the improvement of 
albuminuria was considerable. The high levels of urea, 
uric acid, and creatinine in the urine of T1D rats are due 
to increased production of these parameters. Diabetic 
hyperglycemia directly contributed to hypertension, 
change in hemodynamic, and change in base membrane 
structure of glomerular capillary, and thereby plays an 
important role in albuminuria (42). Therefore, insulin 
and INP correct albuminuria through improvement of 
glucose homeostasis and correction of hemodynamic 
parameters.  
In the current study, T1D increased the gene 
expression and concentrations of KIM-1 and NGAL 
proteins in urine. However, insulin and INP caused a 
significant decrease in KIM-1 and NGAL gene expression 
and the level of these proteins in urine. KIM-1, an 
extracellular protein, is overexpressed in T1D and is 
one of the biomarkers for evaluation of kidney damage 
(43). NGAL is also a ubiquitous lipocalin iron-carrying 
protein that is attached to gelatinase in specific granules 
of neutrophil and acts as a biomarker in ischemic renal 
injury and repair processes (44). In agreement with our 
results, it has been documented that kidney damage in 
DM increased the renal expression of KIM-1 and NGAL 
(45). We previously showed that gene expression and 
urinary levels of KIM-1 and NGAL significantly increase 
in T1D rats (46). As one important limitation in our 
study, histology of kidneys was not evaluated. However, 
another study revealed that hyperglycemia-induced by 
diabetes results in damage to the extracellular matrix 
that is followed by increased vascular permeability, 
impaired blood flow, ischemia and hypoxia, and 
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subsequently diabetic nephropathy (47). It seems 
that T1D- induced hyperglycemia is the main cause 
of NGAL and KIM-1 up-regulation. Results of other 
researchers confirm this hypothesis. They showed that 
hyperglycemia by T1D is the main factor involved in 
NGAL overexpression (48). Not surprisingly, therefore, 
expression of NGAL and KIM-1 increase in T1D rats. 
However, the considerable effects of orally encapsulated 
INPs on expression of NGAL and KIM-1 genes compared 
with insulin is an important point that indicates the 
importance of nanoparticles in drug delivery in our 
study. Overexpression of NGAL and KIM-1 in urine, but 
not in plasma, highlights the potential of these proteins 
as the markers of T1D-induced renal damage. 
Conclusion
To date, therapy by injectable insulin has been the best 
choice to overcome T1D complications. The important 
message of the current study is that orally administrated 
INPs have remarkable effects on improvement of body 
weight, glucose homeostasis, lipid profile, and other 
serum and renal markers in T1D rats in comparison to 
injectable insulin. However, administration of oral INPs 
for DM patients requires further investigation.
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